Epitope base editing: Non-malignant stem cells are going undercover.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 37922877.
- Also identified by DOI 10.1016/j.stem.2023.09.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Engineered hematopoietic stem cells can be shielded from targeted immunotherapy. Recently published in Nature, Casirati et al. utilized single-base editing of epitopes implicated in acute myeloid leukemia and healthy hematopoiesis to alter their antibody and chimeric antigen receptor (CAR) T recognition while preserving their ligand binding and enzymatic function.
Medical subject headings
- Receptors, Chimeric Antigen
- Leukemia, Myeloid, Acute